Straits Times Index
3,072.92 -11.78 (-0.38%) Nikkei
33,486.89 +165.67 (+0.50%) Hang Seng
17,029.61 +36.17 (+0.21%) FTSE 100
7,423.46 -31.78 (-0.43%) Bitcoin USD
37,798.64 -325.41 (-0.85%) CMC Crypto 200
780.81 -4.69 (-0.60%)
Agios Pharmaceuticals, Inc. (AGIO)
After hours:
| Previous close | 22.20 |
| Open | 22.36 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's range | 21.91 - 22.91 |
| 52-week range | 19.80 - 31.87 |
| Volume | |
| Avg. volume | 544,543 |
| Market cap | 1.241B |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.94 |
| Earnings date | 21 Feb 2024 - 26 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.00 |
ZacksAgios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment
Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.
GlobeNewswireAgios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that clinical proof-of-concep
Insider MonkeyAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript November 2, 2023 Agios Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.64, expectations were $-1.69. Operator: Good day and thank you for standing by. Welcome to the Agios Pharmaceuticals Incorporated quarter three 2023 earnings conference call. At this time, all participants are in a listen-only […]
